<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549054</url>
  </required_header>
  <id_info>
    <org_study_id>E5501-G000-012</org_study_id>
    <nct_id>NCT01549054</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501</brief_title>
  <official_title>A Single-center, Randomized, Open-label, Two-part Study to Evaluate Bioavailability of Prototype Third-generation Formulations of E5501 Relative to Second-generation Tablet Formulation in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in healthy subjects. There are two parts to the study. In the first part of
      the study each subject will receive a single 10mg dose of each of the four formulations of
      E550. Based on the results from Part 1, an optimal formulation will be selected for further
      evaluation in Part 2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma concentrations of drug for each dose over time as measured by AUC, CMAX, TMax</measure>
    <time_frame>133 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma concentrations of drug for each dose over time as measured by AUC, CMAX, TMax with and without food</measure>
    <time_frame>133 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>10-mg dose of E5501 2G tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10-mg dose of E5501 cyclodextrin oral solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10-mg dose of E5501-P21% powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10-mg dose of E5501 lipid-based oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10-mg dose of E5501 2G tablet</intervention_name>
    <description>Treatment A: Single 10-mg dose of E5501 2G tablet</description>
    <arm_group_label>10-mg dose of E5501 2G tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10-mg dose of E5501 cyclodextrin oral solution</intervention_name>
    <description>Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution</description>
    <arm_group_label>10-mg dose of E5501 cyclodextrin oral solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10-mg dose of E5501-P21% powder</intervention_name>
    <description>Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension</description>
    <arm_group_label>10-mg dose of E5501-P21% powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10-mg dose of E5501 lipid-based oral</intervention_name>
    <description>Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension</description>
    <arm_group_label>10-mg dose of E5501 lipid-based oral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult men and women (age ≥ 18 to ≤ 55 years)

          -  Body mass index ≥ 18.0 kg/m2 and ≤ 32.0 kg/m2 at the time of screening and baseline of
             Treatment Period 1

          -  Platelet count between 120 x 109/L and 300 x 109/L at baseline of each Treatment
             Period 1, 3, and 5

          -  Women of child bearing potential must agree to use a highly effective method of
             contraception, other than estrogen-based hormonal contraceptives, during the Treatment
             Phase of the study.

        In addition, other standard criteria for healthy subjects will be used.

        Exclusion Criteria:

          -  Evidence of clinically significant cardiovascular, hepatic, gastrointestinal, renal,
             respiratory, endocrine, hematologic, neurologic, or psychiatric disease or
             abnormalities or a known history of any gastrointestinal surgery that could impact the
             PK of study drug

          -  Agents associated with thrombotic events (including oral contraceptives) must be
             discontinued within 30 days of first study drug administration

          -  Evidence of organ dysfunction or any clinically significant event or illness in the
             subject's medical history, e.g., history of splenectomy.

          -  History of arterial or venous thrombosis, including partial or complete thrombosis
             (e.g., stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis,
             or pulmonary embolism). Known family history of hereditary thrombophilic disorders
             (e.g., Factor V Leiden, antithrombin III deficiency, etc.)

          -  Hemoglobin less than the lower limit of normal levels.

        In addition, other standard criteria for healthy subjects will be used.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhaskar Rege</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

